Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Abbott licenses development, marketing rights to Theragyn from Antisoma

Oct. 29, 1999

Clinical data presented for Avax's autologous cancer vaccines

Oct. 29, 1999

Vical receives orphan drug status for Allovectin-7

Oct. 28, 1999

StessGen begins trial of HspE7 for anal dysplasia

Oct. 27, 1999

Development of OvaRex is now sole focus for AltaRex

Oct. 26, 1999

Human trials initiated for IL-13 cytotoxin under development by NeoPharm

Oct. 20, 1999

AltaRex reports new partnering plans for OvaRex MAb

Oct. 19, 1999

ImmunoGen presents positive pharmacokinetic data for huC242-DM1/SB-408075

Oct. 19, 1999

Neurocrine Biosciences' NBI-3001 granted fast track designation

Oct. 18, 1999

Immune Response reports data from phase I colon cancer vaccine study

Oct. 18, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.